A multidisciplinary approach to the management of breast cancer, part 1: Prevention and diagnosis

Mayo Clinic Proceedings

Volumn 82, Issue 8, 2007, Pages 999-1012

  Pruthi, Sandhya ^a   Brandt, Kathleen R ^a   Degnim, Amy C ^a   Goetz, Matthew P ^a   Perez, Edith A ^b   Reynolds, Carol A ^a   Schomberg, Paula J ^a   Dy, Grace K ^a   Ingle, James N ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROSTENEDIOL; AROMATASE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; LAPATINIB; LETROZOLE; MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; TRASTUZUMAB;

BREAST BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CARCINOMA IN SITU; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DIGITAL RADIOGRAPHY; DRUG MECHANISM; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; GENE MUTATION; GENETIC SUSCEPTIBILITY; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; LEG CRAMP; LIFESTYLE; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; MOLECULAR EPIDEMIOLOGY; MUSCULOSKELETAL DISEASE; ONCOGENE; OVARIECTOMY; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TUMOR SUPPRESSOR GENE; VAGINA DISCHARGE; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 34547632366     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.8.999     Document Type: Conference Paper

References (158)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Berry DA, Cronin KA, Plevritis SK, et al, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
3. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354:270-282.
4. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2:133-140.
5. McTiernan A. Behavioral risk factors in breast cancer: can risk be modified? Oncologist. 2003;8:326-334.
6. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:629-642.
7. Rossouw JE, Anderson GL, Prentice RL, et al, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
8. Anderson GL, Limacher M, Assaf AR, et al, Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
9. Grabrick DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000;284:1791-1798.
10. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025-2032.
11. Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94:1773-1779.
12. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst. 1993;85:892-897.
13. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229-237.
14. Page DL, Jensen RA, Simpson JF, Dupont WD. Historical and epidemiologic background of human premalignant breast disease. J Mammary Gland Biol Neoplasia. 2000;5:341-349.
15. Mincey BA. Genetics and the management of women at high risk for breast cancer. Oncologist. 2003;8:466-473.
16. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 2000;26:291-302.
17. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology. 2004 Jan;230:29-41. Epub 2003 Nov 14.
18. Hamajima N, Hirose K, Tajima K, et al, Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87:1234-1245.
19. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998;279:535-540.
20. Hollingsworth AB, Singletary SE, Morrow M, et al. Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg. 2004;187:349-362.
21. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
22. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of the early-onset breast cancer: implications for risk prediction. Cancer. 1994;73:643-651.
23. Dua RS, Isacke CM, Gui GPH. The intraductal approach to breast cancer biomarker discovery. J Clin Oncol. 2006;24:1209-1216.
24. Kriege M, Brekelmans CTM, Boetes C, et al, Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351:427-437.
25. Saslow D, Boetes C, Burke W, et al, American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89.
26. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77-84.
27. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002 May 23;346:1609-1615. Epub 2002 May 20.
28. Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med. 1989;320:479-484.
29. Fisher B, Costantino JP, Wickerham DL, et al, National Surgical Ajuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371-1388.
30. Cuzick J, Forbes J, Edwards R, et al, IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817-824.
31. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98-101.
32. Veronesi U, Maisonneuve P, Costa A, et al, Italian Tamoxifen Prevention Study Group. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 1998;352:93-97.
33. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
34. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial [published correction appears in JAMA. 1999;282:2124]. JAMA. 1999;281:2189-2197.
35. Martino S, Cauley JA, Barrett-Connor E, et al, CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751-1761.
36. Barrett-Connor E, Mosca L, Collins P, et al, Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-137.
37. Vogel VG, Costantino JP, Wickerham DL, et al, National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [published correction appears in JAMA. 2006;296:2926]. JAMA. 2006 Jun 21;295;2727-2741. Epub 2006 Jun 5.
38. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006 Jun 21;295:2742-2751. Epub 2006 Jun 5.
39. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol. 2005;23:1636-1643.
40. Chlebowski RT, Col N, Winer EP, et al, American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002;20:3328-3343.
41. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer [published correction appears in J Natl Cancer Inst. 2000;92:275]. J Natl Cancer Inst. 1999;91:1829-1846.
42. Kalidas M, Brown P. Aromatase inhibitors for the treatment and prevention of breast cancer. Clin Breast Cancer. 2005;6:27-37.
43. Fletcher SW, Elmore JG. Clinical practice: mammographic screening for breast cancer. N Engl J Med. 2003;348:1672-1680.
44. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA. 2005;293:1245-1256.
45. American College of Radiology. ACR BI-RADS-Mammography. In: ACR Breast Imaging Reporting and Data System, Breast Imaging Atlas. 4th ed. Reston, Va: American College of Radiology; 2003:230-234.
46. Kerlikowske K, Grady D, Barclay J, Sickles EA, Emster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA. 1996;3:33-38.
47. Myles J, Duffy S, Nixon R, et al. Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. Rev Epidemiol Sante Publique. 2001;49:471-475.
48. Brekelmans CTM, Seynaeve C, Barrels CC, et al, Rotterdam Committee for Medical and Genetic Counseling. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19:924-930.
49. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260-1268.
50. Pisano ED, Gatsonis C, Hendrick E, et al, Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening [published correction appears in N Engl J Med. 2006;355:1840]. N Engl J Med. 2005 Oct 27;353:1773-1783. Epub 2005 Sep 16.
51. Morton MJ, Whaley DH, Brandt KR, Amrami KK. Screening mammograms: interpretation with computer-aided detection - prospective evaluation. Radiology. 2006 May;239:375-383. Epub 2006 Mar 28.
52. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002;225:165-175.
53. Kaplan SS. Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue. Radiology. 2001;221:641-649.
54. Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography to screen women with mammographically dense breasts. AJR Am J Roentgenol. 2003;181:177-182.
55. Robson M. Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations. Clin Breast Cancer. 2004;5:260-268.
56. Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology. 2000;215:267-279.
57. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317-1325.
58. Lee CH, Smith RC, Levine JA, Troiano RN, Tocino I. Clinical usefulness of MR imaging of the breast in the evaluation of the problematic mammogram. AJR Am J Roentgenol. 1999;173:1323-1329.
59. Liberman L, Morris EA, Dershaw DD, Abramson AF, Tan LK. MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol. 2003;180:901-910.
60. Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology. 1993;187:493-501.
61. Orel SG, Schnall MD, Powell CM, et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology. 1995;196:115-122.
62. Bedrosian I, Schlencker J, Spitz FR, et al. Magnetic resonance imagingguided biopsy of mammographically and clinically occult breast lesions. Ann Surg Oncol. 2002;9:457-461.
63. Lehman CD, Gatsonis C, Kuhl CK, et al, ACRIN Trial 6667 Investigators Group. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007 Mar 29;356:1295-1303. Epub 2007 Mar 28.
64. Liberman L, Morris EA, Kim CM, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. AJR Am J Roentgenol. 2003;180:333-341.
65. Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol. 2003;181:619-626.
66. Parker SH, Burbank F, Jackman RJ, et al. Percutaneous large-core breast biopsy: a multi-institutional study. Radiology. 1994;193:359-364.
67. Liberman L, Evans WP III, Dershaw DD, et al. Radiography of microcalcifications in stereotaxic mammary core biopsy specimens. Radiology. 1994;190:223-225.
68. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
69. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94:1546-1554.
70. Emster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr. 1997;22:151-156.
71. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E, National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: intraductal carcinoma (ductal carcinoma in situ). Cancer. 1995;75:1310-1319.
72. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328:1581-1586.
73. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993-2000.
74. Julien JP, Bijker N, Fentima IS, et al, EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Lancet. 2000;355:528-533.
75. Houghton J, George WD, Cuzick J, Duggan C, Fentima IS, Spittle M, UK Coordinating Committee on Cancer Research, Ductal Carcinoma in situ Working Party, DCIS trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95-102.
76. Lagios MD, Silverstein MJ. Outcomes and factors impacting local recurrence of ductal carcinoma in situ [letter]. Cancer. 2000;89:2323-2325.
77. MacDonald HR, Silverstein MJ, Mabry H, et al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg. 2005;190:521-525.
78. Borger J, Kemperman H, Hart A, Peterse H, van Dongen J, Bartelink H. Risk factors in breast-conservation therapy. J Clin Oncol. 1994;12:653-660.
79. Guidi AJ, Connolly JL, Harris JR, Schnitt SJ. The relationship between shaved margin and inked margin status in breast excision specimens. Cancer. 1997;79:1568-1573.
80. Vicini FA, Kestin LL, Goldstein NS, Baglan KL, Pettinga JE, Martinez AA. Relationship between excision volume, margin status, and tumor size with the development of local recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. J Surg Oncol. 2001;76:245-254.
81. Cao D, Lin C, Woo SH, Vang R, Tsangaris TN, Argani P. Separate cavity margin sampling at the time of initial breast lumpectomy significantly reduces the need for reexcisions. Am J Surg Pathol. 2005;29:1625-1632.
82. Silverstein MJ, Lagios MD, Grosehn S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455-1461.
83. Rampaul RS, Valasiadou P, Pinder SE, et al. Wide local excision with 10 mm clearance without radiotherapy for DCIS. Eur J Cancer. 2001;37(suppl 5):15.
84. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006 Mar 1;24:1031-1036. Epub 2006 Feb 6.
85. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.
86. McKinney CD, Frierson HF Jr, Fechner RE, Wilhelm MC, Edge SB. Pathologic findings in nonpalpable invasive breast cancer. Am J Surg Pathol. 1992;16:33-36.
87. Elston CW, Ellis IO. Pathologic prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
88. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma: a reproducible study. Cancer. 1994;73:2765-2770.
89. Robbins P, Pinder S, de Klerk N, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 1995;26:873-879.
90. Pinder SE, Murray S, Ellis IO, et al. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer. 1998;83:1529-1539.
91. Greene FL, Page D, Fleming I, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002:255-282.
92. Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology. 1979;3:467-488.
93. Bast RC Jr, Ravdin P, Hayes DF, et al, American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology [published corrections appear in J Clin Oncol. 2001;19:4185-4188, 2002;20:2213]. J Clin Oncol. 2001;19:1865-1878.
94. Allred DC, Bryant JL, Land S, et al. Estrogen receptor status as a predictor of the effectiveness of tamoxifen in DCIS: findings of the NSABP Protocol B-24. Mod Pathol. 2003;16:21A.
95. Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980(12 suppl);46:2884-2888.
96. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
97. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel Members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005 Oct; 16:1569-1583. Epub 2005 Sep 7.
98. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene. 1995;159:19-27.
99. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
100. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06: 10-year pathologic and clinical prognostic discriminants. Cancer. 1993;71:2507-2514.
101. Canavese G, Catturich A, Vecchio C, et al. Prognostic role of lymphnode level involvement in patients undergoing axillary dissection for breast cancer. Eur J Surg Oncol. 1998;24:104-109.
102. Tuttle TM. Sentinel lymph node biopsy: preferred method of axillary staging for breast cancer. Minerva Ginecol. 2005;57:293-303.
103. Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001;92:1368-1377.
104. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106:4-16.
105. American Society of Breast Surgeons. Consensus statement on guidelines for performing sentinel lymph node dissection in breast cancer. Available at: www.breastsurgeons.org/slnd.shtml. Accessed May 7, 2007.
106. Temple LK, Baron R, Cody HS, et al. Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol. 2002;9:654-662.
107. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life: results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006 Feb;95:279-293. Epub 2005 Sep 15.
108. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 2006; 56:37-47.
109. Cserni G, Amendoeira I, Apostolikas N, et al, European Working Group for Breast Cancer Screening Pathology. Pathological workup of sentinel lymph nodes in breast cancer: review of current data to be considered for the formulation of guidelines. Eur J Cancer. 2003;39:1654-1667.
110. Brogi E, Torres-Matundan E, Tan LK, Cody HS III. The results of frozen section, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients. Ann Surg Oncol. 2005 Feb;12:173-180. Epub 2005 Feb 4.
111. Lucci A, Mackie L, Beitsch P, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection, versus SLND alone in the American College of Surgeons Oncology Group (ACOSOG) Trial Z0011 [abstract]. Ann Surg Oncol. 2006;13(2, suppl):4. Abstract 9.
112. Abdessalaam SF, Zervos EE, Prasad M, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg. 2001;182:316-320.
113. Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999;17:1720-1726.
114. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140-1151.
115. Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190:543-550.
116. Lambert LA, Ayers GD, Hwang RF, et al. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2006 Mar;13:310-320. Epub 2006 Feb 10.
117. Kocsis L, Svebis M, Boross G, et al. Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg. 2004;70:1019-1024.
118. Smidt ML, Kuster DM, van der Wilt GJ, Thunnissen FB, Van Zee KJ, Strobbe LJ. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands? Ann Surg Oncol. 2005 Dec;12:1066-1072. Epub 2005 Oct 26.
119. Guenther JM, Hansen NM, DiFronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003;138:52-56.
120. Jeruss JS, Winchester DJ, Sener SF, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005 Jan;12:34-40. Epub 2004 Dec 27.
121. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462-468.
122. Zakaria S, Pantvaidya G, Reynolds C, et al. Sentinel node biopsy positive breast cancer patients who do not undergo axillary dissection: are they different? Presented at: American Society of Breast Surgeons 7th Annual Meeting; Baltimore, MD; April 5-9, 2006.
123. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628-3636.
124. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol. 1989;7:1239-1251.
125. Helllman S. Karnofsky Memorial Lecture: natural history of small breast cancers. J Clin Oncol. 1994;12:2229-2234.
126. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005;23:2716-2725.
127. Page DL. Prognosis and breast cancer: recognition of lethal and favorable prognostic types. Am J Surg Pathol. 1991;15:334-349.
128. D'Eredita' G, Giardina C, Martellotta M, Natale T, Ferrarese F. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer. 2001;37:591-596.
129. de Mascarel I, Binichon F, Durand M, et al. Obvious peritumoural emboli: an elusive prognostic factor reappraised: multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 1998;34:58-65.
130. Lee AK, Delellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol. 1990;8:1457-1465.
131. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol. 1994;12:454-466.
132. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 1997;47:28-51.
133. Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol. 2006;24:2113-2122.
134. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998;52:227-237.
135. Gebauer G, Fehm T, Lang N, Jager W. Tumor size, axillary nodal status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat. 2002;75:167-173.
136. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
137. Thorpe SM, Christensen IJ, Rasmussen BB, Rose C. Short recurrence-free survival associated with high estrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer. 1993;29A:971-977.
138. Sancho-Garnier H, Delarue JC, Mouriesse H, et al. Is the negative prognostic value of high estrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product? Eur J Cancer. 1995;31A:1851-1855.
139. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate therapy for young women with oestrogen-receptor positive breast cancer? Lancet. 2000;355:1869-1874.
140. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-325.
141. Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003. World Health Organization Classification of Tumors series.
142. Pritchard KI, Shepherd L, O'Malley FP, et al, National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103-2111.
143. Doswett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006 May; 17:818-826. Epub 2006 Feb 23.
144. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res. 2003;9:1039-1046.
145. Slamon, DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
146. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [published correction appears in N Engl J Med. 2007;356:1487]. N Engl J Med. 2006;355:2733-2743.
147. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591-602.
148. Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res. 2004;10:1392-1400.
149. Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol. 1998;16:557-566.
150. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-752.
151. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003 Jul 8:100:8418-8423. Epub 2003 Jun 26.
152. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
153. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. A' Engl J Med. 2002;347:1999-2009.
154. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671-679.
155. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006 Apr 10;24:1665-1671. Epub 2006 Feb 27.
156. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004 Dec 30; 351:2817-2826. Epub 2004 Dec 10.
157. Esteva FJ, Sahin AA, Cristofanilli M, et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res. 2005;11:3315-3319.
158. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8(3):R25. Epub 2006 May 31.